RPG Life Sciences Limited (RPGLIFE) — Annual Report

· NSE 🔴 High Importance Neutral

The filing announces the 19th AGM of RPG Life Sciences Limited scheduled for July 23, 2026, via video conferencing, and includes the Annual Report FY 2025-26 and Business Responsibility and Sustainability Report. It provides details on the notice, e-voting process, and links to the documents. The Annual Report highlights RPG Life Sciences' position as a US$5.2 billion diversified conglomerate, its business segments (Domestic Formulations, International Formulations, APIs), financial performance (₹707.5 crores revenue, 8.3% growth, 24.4% EBITDA margin, ₹275 crores cash reserves), therapy-wise product growth (Nephrology 55.2%, Rheumatology 40.2%, Oncology 23.2%), and strategic focus on market expansion and inorganic growth.

📄 View Original Announcement (PDF)

About RPG Life Sciences Limited (RPGLIFE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹3,791.57 Cr P/E: 32.9

View full RPGLIFE stock details →

📡 Get AI alerts when RPGLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track RPGLIFE — Free

📊 More RPGLIFE filings

See all RPGLIFE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when RPGLIFE files new disclosures

Track RPGLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track RPGLIFE — Free

Free account · 2 AI queries/day